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Complement is a tightly controlled arm of the innate immune system, facilitating
phagocytosis and killing of invading pathogens. Factor H (FH) is the main fluid-phase
inhibitor of the alternative pathway. Many pathogens can hijack FH from the host
and protect themselves from complement-dependent killing. Candida albicans is a
clinically important opportunistic yeast, expressing different FH binding molecules on
its cell surface, which allow complement evasion. One such FH binding molecule is
the transmembrane protein “High affinity glucose transporter 1” (Hgt1p), involved in
glucose metabolism. This study demonstrated that Hgt1p transcription and expression
is induced and highest at the low, but physiological glucose concentration of 0.1%.
Thus, this concentration was used throughout the study. We also demonstrated the
transport of Hgt1p to the fungal cell wall surface by vesicle trafficking and its release
by exosomes containing Hgt1p integrated in the vesicular membrane. We corroborated
Hgt1p as FH binding molecule. A polyclonal anti-Hgt1p antibody was created which
interfered with the binding of FH, present in normal human serum to the fungal cell
wall. A chimeric molecule consisting of FH domains 6 and 7 fused to human IgG1 Fc
(FH6.7/Fc) even more comprehensively blocked FH binding, likely because FH6.7/Fc
diverted FH away from fungal FH ligands other than Hgt1p. Reduced FH binding to
the yeast was associated with a concomitant increase in C3b/iC3b deposition and
resulted in significantly increased in vitro phagocytosis and killing by human neutrophils.
In conclusion, Hgt1p also exhibits non-canonical functions such as binding FH after its
export to the cell wall. Blocking Hgt1p-FH interactions may represent a tool to enhance
complement activation on the fungal surface to promote phagocytosis and killing of
C. albicans.
Keywords: fungal infections, Candida albicans, complement system, immune evasion, factor H
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INTRODUCTION
Candida albicans is a normal resident of the human oral cavity,
the gastrointestinal tract (Strijbis et al., 2014) and vaginal mucous
membranes (Peters et al., 2014). The human immune system
plays a key role in inhibiting the proliferation of C. albicans
in colonized areas. However, in an immunocompromised
host, C. albicans can lead to local or systemic opportunistic
infections (Musial et al., 1988). Virulence factors such as
surface-expressed or secreted proteins play a pivotal role in
enabling C. albicans to facilitate host blood dissemination
(Mayer et al., 2013). Dimorphism is a crucial virulence
factor of C. albicans that enables the fungus to change its
shape in response to the external stimuli, thus facilitating
its ability to colonize its host and cause invasive disease.
The filamentous form empowers the fungus to induce tissue
invasion and ultimately reach the blood vessels. The reversion
to the yeast form enables C. albicans to disseminate through
the bloodstream and cause multi-organ infection (Brand,
2012). The therapeutic options for invasive fungal infections
have become increasingly limited (Roemer and Krysan,
2014).
Innate immunity plays a crucial role in antifungal defense.
A critical arm of innate defenses is complement, a tightly
controlled system which is able to recognize and kill the
pathogens that breach host epithelial and mucosal barriers
(Merle et al., 2015). Three different complement activation
pathways commence rapidly following infection. The purpose
of all three pathways is to activate C3. The resulting fragments
of C3 that are generated play different crucial roles to combat
invasion by microorganisms. Opsonization of the invading
microbe with iC3b is critical for its phagocytosis, the most
effective mechanism to clear fungi (Speth et al., 2008). The
complement system has to be regulated to prevent uncontrolled
activation and the attack of host cells. In the fluid phase,
this regulation is mainly facilitated by complement factor
H (FH), a protein composed of 20 short consensus repeats
(Kopp et al., 2012). The major opportunistic fungi such as
Candida spp. have developed a strategy to limit complement
action by hijacking FH from the host by employing specific
FH binding molecules on their cellular surfaces (Meri et al.,
2004; Kraiczy and Wurzner, 2006; Vogl et al., 2008), thereby
mimicking the host cells. Hgt1p, a transmembrane protein
involved in glucose metabolism in C. albicans is also a FH
binding molecule (Lesiak-Markowicz et al., 2011). Recently,
HGTs were identified as a large family of glucose transporters in
C. albicans (Hgt1p to Hgt20p). They share 10–93% of sequence
identity and the expression of the HGTs genes is related to
the glucose concentration in the growth medium (Fan et al.,
2002).
Here we show that the expression of HGT1 was highest
at low (relative to enriched media), but physiological
glucose concentrations, was associated with intracellular
and extracellular vesicles, and also plays a non-canonical
role by down-modulating phagocytosis and killing by
human neutrophils. Blocking FH binding to fungi enhanced
phagocytosis.
MATERIALS AND METHODS
Reagents and Media
Fluorescein isothiocyanate (FITC), Ficoll Paque-1077,
RPMI 1640 medium with L-glutamine, glucose free,
HEPES without sodium bicarbonate, Phosphate Buffered
Saline (PBS), TRIzole-reagent, Sodium Chloride (NaCl),
Ethylenediaminetetraacetic acid (EDTA), Dithiothreitol
(DTT), Tris hydrochloride (Tris-HCl), Potassium chloride
(KCl), Carbonate-bicarbonate, Tween-20, D-Sorbitol,
1,4-Piperazinediethanesulfonic acid sodium salt (PIPES),
protease inhibitor cocktail, Phenylmethylsulfonylfluorid (PMSF)
were obtained from Sigma (St. Louis, MO, United States). Bovine
Serum Albumin (BSA), peptone from soy and D-(+) glucose were
purchased from Carl Roth GmbH (Karlsruhe, Germany). Yeast
extract and granulated agar were obtained from BD Biosciences
(San Diego, CA, United States). EvaGreen was purchased from
BioRad (Hercules, CA, United States). The qScript 1-step fast
Kit Reverse Transcriptase was obtained from Quanta Bioscience
(Beverly, MA, United States). Goat anti-human complement
FH was purchased from Calbiochem. Phycoerythrin (PE)-
conjugated anti-C3b/iC3b was obtained from Biolegend
(San Diego, CA, United States). Rabbit anti-goat IgG FITC
conjugated was purchased from Life Technologies (Carlsbad,
CA, United States). The immune coat gold goat anti-rabbit IgG
20 nm was obtained from Innova bioscience, Expedeon (San
Diego, CA, United States). Zymolyase was purchased from AMS
Biotechnology (Abingdon, United Kingdom). Pioloform coated
copper grids were obtained from Agar Scientific (Stansted,
United Kingdom).
Fungal Strains
The strains used in this study were C. albicans parental strain
SN152 (an Arg−/Leu−/His− auxotrophic strain), used as parental
strain for knocking out HGT1 according to standard protocols
(Noble and Johnson, 2005), as well as hgt11/1 homozygous
null mutant and hgt11/1::HGT1 complemented control strain,
both generated previously (Lesiak-Markowicz et al., 2011). The
strains were grown on YPD agar (Yeast extract 1%, Peptone 2%,
and Dextrose 2%). Prior to all experiments, a colony each of all
the strains was cultured in liquid medium YP 0.1% of glucose
(Yeast extract 1%, Peptone 2%) or, in selected experiments, in
YP 0.3% of glucose or YPD (containing 2% glucose) overnight
(ON) at 30◦C under agitation. Both, parental and mutant strains
produce similar biomasses after incubation at low (0.1%) glucose
concentrations. Approximately three times higher biomasses of
parental and mutant strains were produced at high (2%) glucose
concentrations. No differences in biomass between the two
strains were detected when grown for 48 h in media containing
0.1, 0.3, or 2% of glucose (data not shown).
Anti-Hgt1p Antibody
A polyclonal anti-Hgt1p antibody was commercially generated
by ProteoGenix, Schiltigheim, France. The sequence of Hgt1p
(NCBI reference XP_712952.1) was aligned with known protein
structures data bank. The structure of 4GBY.PDB was selected
as 29% homologous to Hgt1p. Selected structure was aligned
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with XP_712952.1 to identify regions that can be remodeled
by sequence homology, then analyzed by 3D model to confirm
the sequence on the extracellular side of C. albicans membrane
(Figure 1). Within the sequence of Hgt1p used to generate the
antibody, VMMYYIVYIFFQMAGYSGNSNLVASS, the peptide
in bold was selected from an extracellular portion of the molecule
between amino acids 306 and 315 from a total length of 545
amino acids. This synthetic peptide (location shown in Figure 1,
orange and blue arrows) was used by ProteoGenix to immunize
rabbits. The antibodies were used in Western blot analysis of cell
membranes, cell wall extracts and whole cells of C. albicans SN152
in comparison with the hgt11/1 null mutant to validate that
the antibody binds to an epitope on the former, and thus likely
to Hgt1p (hence termed anti-Hgt1p), but only to a negligible
extent to the null mutant (data not shown). Rabbit anti-human
IgG (DAKO, Glostrup, Denmark) was used as irrelevant (rabbit)
antibody and thus as a control for blocking by rabbit anti-Hgt1p.
No differences in growth between the parental strain SN152
and SN152 incubated with different dilutions of anti-Hgt1p were
detected over a period of 48 h (data not shown).
FH6.7/Fc Chimeric Molecule
Cloning, expression in CHO cells and purification from cell
culture supernatants of a chimeric protein comprising human FH
domains 6 and 7 fused to human IgG1 Fc (FH6.7/Fc) has been
described previously (Shaughnessy et al., 2014).
mRNA Isolation and Quantitative
Polymerase Reaction Chain (qPCR)
SN152 and hgt11/1 strains were grown in YP 0.1% glucose,
YP 0.3% glucose and YPD liquid medium overnight at 30◦C.
The mRNA extraction was adapted from previous methods (Rio
et al., 2010) and measured spectrophotometry at 260 nm; purity
determined by the A260/A280 ratio. The qPCR assays were
processed using 2 ng/µl of the extracted mRNA. ACTIN-1 was
FIGURE 1 | 3D schematic representation of Hgt1p. The polyclonal antibody
anti-Hgt1p, used in this project, was commercially generated by ProteoGenix,
Schiltigheim, France. It recognizes an epitope exposed in an extracellular
portion of Candida albicans cell membrane (upper arrows).
used as a control. The sequences of the forward (F) and reverse
(R) primers were as follows:
HGT1F:5′-ACTTCATCCATGGCTTTGGGT-3′;
HGT1R:5′-GCAGAACCGAAACCAACACC-3′
ACT1F:5′-TGGTGATGAAGCCCAATCCA-3′;
ACT1R:5′-TGGAGCTTCGGTCAACAAAAC-3′.
The conditions for HGT1 and ACT1 qPCR were: initial cycle
95◦C/5 min, followed by 39 cycles of 95◦C/10 s, annealing
temperature 57◦C/30 s followed by 72◦C/30 s. The PCR products
were analyzed by electrophoresis in 1% agarose gel. The purity
of qPCR amplification was determined by melt curve analysis.
The HGT1 expression was evaluated as a relative normalized
expression using ACT1 as the housekeeping gene by the Bio-Rad
CFX manager software.
HGT1 Sequencing
The DNA amplicons were purified with ExoSAP-IT (USB
Corporation, Affymetrix, Santa Clara, CA, United States).
The same primers described above were used to perform
the sequencing PCR. The reaction was performed as follows:
initial cycle at 96◦C/1 min, followed by 25 cycles of 96◦C/10 s,
annealing temperature at 50◦C/5 s followed by 60◦C/4 min.
The products were purified using BigDye XTerminator kit
(Applied Biosystems, Carlsbad, CA, United States). Sequencing
analysis was performed by ABI 3500 Genetic Analyzer (Applied
Biosystems, Carlsbad, CA, United States). Subsequently,
sequences were analyzed by Sequencing 5.2 analysis software
(Applied Biosystems).
Preparation of Yeast by High Pressure
Freezing (HPF)
The SN152 and hgt11/1 strains were grown in YP 0.1% glucose
at 30◦C. One drop of each overnight culture (40 µl) was
processed for high pressure freezing cryofixation by Leica EM
PACT 2 (Leica Microsystems, Milton Keynes, United Kingdom),
according to the guidelines of the Microscopy facility of the
University of Aberdeen (Lopes-Bezerra et al., 2018).
Immunogold Hgt1p Labeling
The grids were stained as previously described (Lopes-Bezerra
et al., 2018). The coated grids were blocked by one drop (40 µl)
of blocking buffer (BSA 1% and Tween 0.5% in PBS) for 20 min
at RT. The grids were washed with 40 µl of washing buffer (BSA
0.1% in PBS) and incubated with 1 µg of anti-Hgt1p (100 µg/ml)
in 40 µl washing buffer for 90 min at RT. Subsequently, the
grids were washed with washing buffer and incubated with
an appropriate gold conjugated secondary antibody (1:100) in
blocking buffer. Afterward the grids were washed with PBS
and stained with Uranyl acetate. Samples were visualized by
transmission electron microscopy (TEM) JEM 1400 plus JEOL
(Welwyn Garden City, United Kingdom) and captured by AMT
UltraVUE camera (Woburn, MA, United States). The hgt11/1
null mutant and SN152 strains were stained with anti-Hgt1p,
or with only the secondary gold-conjugated antibody to confirm
antibody specificity.
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C. albicans Protoplast Formation and
Hgt1p Gold Staining of Intracellular
Secretory Pathways Vesicles
Candida albicans protoplasts were obtained as previously
described (Cabezon et al., 2009). Briefly, the overnight culture of
SN152 strain, grown in YP 0.1% of glucose at 30◦C, was diluted
to OD600 of 0.2 and grown at 30◦C in YP 0.1% of glucose,
200 rpm for 4–6 h to reach the exponential phase (OD600 1–1.6).
The cells were washed twice with a solution of 100 mM Tris,
100 mM EDTA at pH 8.0 and incubated in the same buffer
with 2-mercaptoethanol (1:200) for 30 min at 100 rpm at 30◦C.
Cells were then resuspended in a Sorbitol buffer (1 M sorbitol,
10 mM PIPES solution, pH 6.5) containing 100U Zymolyase and
incubated at gentle shaking for 45 min at 30◦C. The protoplasts
formation was analyzed by light microscopy. Protoplasts were
resuspended in lysis buffer (50 mM Tris-HCl, 1 mM EDTA,
150 mM NaCl, 1 mM DTT, 0.5 mM PMSF, protease inhibitor
cocktail pH 7.5) for disruption.
Disruption was done by homogenization in lysis buffer on
ice (Schuster et al., 2016). The extract was centrifuged using a
bench top centrifuge Eppendorf 5415D at 10,000 g for 5 min. The
supernatant was filtered in 0.2 µm filter and ultra-centrifuged
using Optima MAX Ultracentrifuge (Beckman Coulter), TLA
120.1 rotor at 100,000 g for 1 h at 4◦C. The pellet was resuspended
in 100 µl of PBS. The vesicles were put to adhere on the copper
pioloform coated grids overnight (ON) at 4◦C. The vesicles were
subsequently blocked with one drop (40 µl) of BSA 1% and
Tween 0.5% in PBS for 20 min at room temperature (RT). The
grids were washed with 40 µl washing buffer consisting of BSA
0.1% in PBS and incubated with 1 µg of anti-Hgt1p (100 µg/ml)
in 40 µl of washing buffer for 90 min at RT. Subsequently,
the grids were washed in washing buffer and incubated with
an appropriate gold conjugated secondary antibody (1:100) in
blocking buffer. The grids were washed with PBS and stained with
Uranyl acetate. Samples were visualized by TEM.
Hgt1p Gold Staining of Isolated
Exosomes Released by C. albicans
Candida albicans SN152 strain was grown in 50 ml of YP
0.1% glucose medium at 30◦C. The collected supernatant was
filtered by 0.2 µm filter and ultra-centrifuged by Optima MAX
Ultracentrifuge, rotor Type 70Ti at 100.000 g for 1 h at 4◦C.
The pellet was resuspended in PBS and stained as previously
described for intracellular secretory pathway vesicles Hgt1p gold
staining (Schuster et al., 2016). Sample was visualized by TEM.
The percentage of exosomes and secretory vesicles that were
positive for colloidal gold staining, and thus represented presence
of Hgt1p, was measured.
FH and C3b/iC3b Deposition on
C. albicans Surface by Fluorescence
Activated Cell Sorting (FACS)
SN152, hgt11/1 and hgt11/1::HGT1 reintegrated (both Lesiak-
Markowicz et al., 2011) strains were grown ON in YP 0.1%
glucose. 1 × 106 yeasts were opsonized with 10% of fresh
human serum (NHS) in PBS for 15 min at 37◦C. In some
experiments, the parental strain SN152 was blocked with 1 µg
of anti-Hgt1p antibody, 1 µg of the chimeric molecule FH6.7/Fc
or with 1 µg of an irrelevant rabbit anti-human IgG antibody
(all at 10 µg/ml) for 45 min at 37◦C before opsonization. All
strains were washed in PBS and incubated with anti-FH and
anti-C3b/iC3b PE conjugated antibodies separately, overnight at
4◦C. Yeasts were then washed in PBS and bound FH was detected
with an appropriate secondary antibody FITC conjugated for
60 min at RT. All strains were washed in PBS and fixed with
PBS/PFA 1%. The yeasts were then fluorescence activated cell
sorting (FACS)-gated by SSC vs. FCS density plot and 10,000
events were analyzed. The positive population was detected by
one color fluorescence density plot SSC vs. FITC for anti-FH and
SSC vs. PE for C3b/iC3b using FACS Calibur and Cell Quest Pro
software (BD Biosciences, San Diego, CA, United States).
Purification of Polymorphonuclear
Neutrophils (PMNs)
Fresh blood was obtained from informed consent healthy
human donors, based on a vote of the Innsbruck Medical
University Ethical Committee. Polymorphonuclear neutrophils
(PMNs) were separated from heparinized whole blood by
Ficoll Paque-1077 density gradient centrifugation and hypotonic
erythrocyte lysis (Monari et al., 2002). The PMNs were collected
and resuspended in RPMI medium. The purity of PMNs was
determined by light microscopy.
FACS Analysis of Phagocytosis by PMNs
SN152, hgt11/1 and hgt11/1::HGT1 reintegrated strains were
grown in YP 0.1% glucose liquid medium ON at 30◦C. Yeast cells
(1 × 106) were washed in PBS and opsonized with 10% of fresh
NHS in PBS for 15 min at 37◦C. In a different set up, the parental
strain SN152 was blocked with 1 µg anti-Hgt1p or with 1 µg of
the chimeric FH6.7/Fc (both at 10 µg/ml) for 45 min at 37◦C
before the opsonization. Subsequently, all yeasts were washed
with PBS and stained with FITC in 0.05 M carbonate-bicarbonate
buffer (1 mg/ml) for 15 min at 37◦C (Rudkin et al., 2013).
Fresh human PMNs and fluorescent C. albicans were co-cultured
(PMNs : C. albicans = 1:10) for 30 min at 37◦C/5% CO2 in
glucose RPMI medium and 0.1%. After co-incubation, cells were
centrifuged at 200 g to selectively pellet PMNs and remove
external yeast cells. The PMNs were fixed in PBS/PFA 1%.
Further, the PMNs were gated in SSC vs. FCS density plot and
10,000 events were analyzed. The positive PMNs were detected
by one color fluorescence density plot SSC vs. FITC using FACS
Calibur and Cell Quest Pro. Phagocytic activity was evaluated
as percentage of FITC emission from PMNs, i.e., positive PMNs
were those which contained at least on yeast cell.
PMN Mediated Fungal Killing
Polymorphonuclear neutrophil-mediated killing was assessed by
counting colony forming units (CFUs). SN152, hgt11/1 and
hgt11/1::HGT1 reintegrated strains were grown in YP 0.1%
glucose medium overnight at 30◦C. The strains were opsonized
with fresh 10% NHS/PBS for 15 min at 37◦C. In separate
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experiments, the parental SN152 was blocked with anti-Hgt1p
or with FH6.7/Fc (both 1 µg at 10 µg/ml) for 45 min at 37◦C
and afterward opsonized with 10% NHS/PBS for 15 min at 37◦C.
Fresh human PMNs and Candida were placed in wells of a 96-well
plate (PMNs: C. albicans = 1:10) in RPMI with 0.1% of glucose.
The plate was centrifuged at 800 g to promote yeast and PMNs
interaction. Subsequently the plate was incubated for 30 min
at 37◦C, 5% CO2 and placed on ice to block further killing.
Serial dilutions were carried out by water 0.2% Triton to induce
PMNs lysis (Torosantucci et al., 2000). To assess fungal killing,
yeasts only were used as CFU control. The percent of killing was
evaluated by the following equation (Mota et al., 2015): % of
killing = [(CFU control – CFU test)/CFU control]× 100.
Statistical Analysis
The data reported are expressed as the mean ± standard
deviation (SD) from 3 to 5 separate experiments, performed
at different days. The data were analyzed by unpaired t-test,
or, when comparing more than two groups, with one-way
ANOVA using the parental strain as reference which allows
sample-to-sample p-values. In all experiments a p-value of< 0.05
was considered statistically significant.
Ethics Statement
The Ethics Committee of the Medical University of Innsbruck
confirmed that ethics committee approval is not required for the
use of anonymised leftover specimens from blood donations of
the local blood bank, for scientific purposes.
RESULTS
Glucose Dependent HGT1 Expression
A quantitative real time PCR was performed to analyze regulation
of HGT1 by glucose. The mRNA of parental SN152 and hgt11/1
null mutant strains were extracted and amplified by specific
primers for HGT1 and ACT1. In order to confirm an absence of
signal from the hgt11/1 mutant, the qPCR amplification was
visualized by electrophoresis (Figure 2A and Supplementary
Figure S1). The expression of HGT1 was evaluated by Bio-Rad
CFX manager software as a relative normalized expression by
using ACT1 as a housekeeping gene. HGT1 gene expression in
low glucose medium (0.1%) was significantly higher compared to
high glucose medium (0.3 and 2%) (Figure 2B).
Distribution of Hgt1p on C. albicans and
in Vesicle Trafficking: Hgt1p Present in
Released Exosomes
Candida albicans SN152 strain cryofixed by HPF was stained
with colloidal gold-labeled anti-Hgt1p antibody and subsequently
visualized by TEM to assess Hgt1p distribution on yeast.
Hgt1p (visualized by black dots) was detected intracellularly,
in the cell membrane and on the cell wall of C. albicans
(Figure 3A), especially when focussing on cell membrane
and cell wall (Figure 3B). Inside the fungal cell, Hgt1p was
clearly associated with purified secretory vesicles, in the internal
part of the vesicles (Figure 3C). In contrast, in exosomes
released by C. albicans to the environment, Hgt1p was detected
within the vesicular membrane (Figure 3D). About 50% of the
intracellular vesicles were positive for Hgt1p, in contrast to only
30% in released exosomes. Specificity of antibody staining was
determined using the hgt11/1 null mutant that was stained
with anti-Hgt1p and gold-labeled secondary antibody and with
the SN152 parental strain staining using only the secondary
gold-conjugated antibody. The missing black dots in hgt11/1
or the incubation of only the secondary antibody with the
parental strain confirm the specificity of anti-Hgt1p and exclude
cross-reactions (Supplementary Figure S2).
Deposition of FH and C3b/iC3b on
C. albicans Surface
As revealed by FACS analysis, a significantly higher proportion of
parental SN152 yeast cells bound FH compared to the hgt11/1
null mutant or SN152 pre-incubated with anti-Hgt1p or by the
chimeric molecule FH6.7/Fc (Figure 4A). The hgt11/1 null
mutant strain bound significantly (approximately 40%) less FH
than the parental strain SN152. Preincubation of the latter with
anti-Hgt1p or the chimeric molecule FH6.7/Fc also significantly
lowered FH binding by ∼60 or ∼80%, respectively (Figure 4B).
FIGURE 2 | Glucose dependent HGT1 expression. (A) Electrophoresis of qPCR products (cropped figure from same experiment, Supplementary Figure S1).
(B) Expression of HGT1 normalized to ACT1. The electrophoresis run shown is a representative of three separate experiments. HGT1 expression was normalized to
ACT1, a constitutively expressed housekeeping gene that did not show significant differences in expression at different glucose concentrations. The graph shows the
average of three separate experiments. Bars represent the mean + SD. Significance (∗p < 0.05) was determined by one-way ANOVA, using SN152 for comparison.
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FIGURE 3 | Immunogold staining of C. albicans SN152 grown in physiological low glucose medium (0.1%) after HPF cryofixation visualized by TEM. (A) Intracellular
distribution and Hgt1p detection in the cell membrane and cell wall of C. albicans. (B) Zoomed-in view of Hgt1p in the cell membrane and on the cell wall surface.
(C) Gold staining of secretory pathway vesicles showing Hgt1p protein in the internal part of the vesicle and (D) on exosomes released by C. albicans to the
environment, demonstrating the presence of Hgt1p integrated in the vesicle membrane.
Accordingly, C3b/iC3b deposition on the surface of the hgt11/1
null mutant strain was significantly higher compared to the
parental strain (approximately 1.5 times). Blocking FH binding to
SN152 using anti-Hgt1p or FH6.7/Fc also significantly increased
(by a factor of ∼1.5) C3b/iC3b deposition on the yeast surface
compared to the parental strain. SN152 treated with rabbit
anti-human IgG of irrelevant specificity showed similar C3b/iC3b
deposition as the parental strain (Figure 5).
In vitro Phagocytosis by PMNs
Fluorescence activated cell sorting analysis showed that a
significantly lower fraction of freshly isolated human PMNs
(25.2%) were associated with NHS-opsonized SN152 (parental
strain) compared to NHS-opsonized hgt11/1 null mutant
(51.2%) after 30 min of incubation (Figure 6A; compare graphs
labeled PMNs + SN152 and PMNs + hgt11/1). Incubation of
non-opsonized fungi with PMNs resulted in minimal association
with PMNs (below 5%, data not shown), demonstrating the need
for complement for opsonophagocytosis of Candida. Blocking
FH binding to the parental strain SN152 with anti-Hgt1p or the
chimeric molecule FH6.7/Fc both increased association of fungi
with PMNs [Figure 6A; compare PMNs + SN152 + anti-Hgt1p
(43.4% PMNs positive) and PMNs + SN152 + FH6.7/Fc (63.8%
of PMNs positive) with PMNs+ SN152 (25.2% PMNs positive)].
The cumulative data from five separate experiments [as the % of
PMNs associated with fungi relative to the mixture that contained
NHS-opsonized SN152 incubated with PMNs (black bar)] is
shown in Figure 6B.
Confocal microscopy was carried out to confirm that the
association of C. albicans with PMNs in the FACS assay
in Figure 6 translated to phagocytosis. The hgt11/1 null
mutant showed a higher extent of fluorescent C. albicans cells
internalized in comparison to internalization of parental strain
SN152; the number of PMNs that internalized 1, 4, or 5 hgt11/1
null mutant cells compared to the parental strain reached
statistical significance (Supplementary Figure S3).
To confirm that the FITC fluorescence emission from PMNs
represents the phagocytosis activity (i.e., internalization), an
additional staining by Uvitex 2B was carried out in a separate
set up of experiments to discriminate the internalized (green)
from the PMN-attached yeast cells (blue). The tubes were
placed on ice and the samples were stained with 1 µl of
Uvitex 2B (0.01% in PBS) for 1 min. FACS analysis confirmed
that 16% of PMNs had phagocytosed yeast cells and 5% only
carried yeast cells attached to the membrane (Supplementary
Figure S4).
Killing Assay
Candida albicans killing by human PMNs was significantly more
pronounced for hgt11/1 and SN152 blocked by anti-Hgt1p
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FIGURE 4 | Factor H (FH) binding to C. albicans. (A) Binding of FH present in NHS to C. albicans was analyzed by FACS. Density plots from one representative
experiment are shown. X-axis, fluorescence of FH binding. Gates represent the % of C. albicans cells that stain positively for FH. Y-axis, side scatter (SSC). The
components of the reaction mixture are indicated above each graph. (B) Cumulative data of FH binding to C. albicans. FH binding to SN152, hgt11/1,
hgt1p1/1::HGT1 reintegrated strain, or SN152 pre-incubated with anti-Hgt1p or the chimeric molecule FH6.7/Fc, or with irrelevant rabbit anti-human IgG. Data are
expressed as mean fluorescent intensity (MFI) normalized to SN152 parental strain. Bars represent the normalized mean fold-increase + SD of five separate
experiments ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, by one-way ANOVA, using SN152 for comparison.
or FH6.7/Fc (each approximately 20%) when compared to the
untreated parental strain (Figure 6C).
DISCUSSION
In the present study we increased the knowledge on Hgt1p
expression showing a higher expression of HGT1 in media with
low glucose concentration (0.1%) – not unexpected for a glucose
transporter – which resembles the physiological concentration in
humans (Buu and Chen, 2014). This concentration was therefore
used for all following experiments. In this respect, it is important
to mention that several in vitro mycology studies use YPD, which
contains a completely unphysiological glucose concentration (of
2%), even for diabetic humans.
Hgt1p was detected within the cell (Figures 3A–C), the cell
membrane and cell wall (Figures 3A,B) and was associated with
both intracellular and extracellular vesicles (Figures 3C,D). Based
on these findings it is likely that Hgt1p is being transported in
intracellular secretory vesicles and accumulates not only in the
cell membrane, but also on the cell wall, which is corroborated
by the fact that 60 nm AmBisome liposomes can transit
intact through the C. albicans cell wall (Walker et al., 2018).
One may hypothesize that Hgt1p plays not only a canonical
transmembrane role in glucose transport, but, when it binds
FH on the surface of the yeast cell wall, it serves an additional
non-canonical role as a moonlighting protein (Karkowska-
Kuleta and Kozik, 2014), by interfering with host cells, enabling
C. albicans to evade the immune attack, detailed below.
During co-evolution C. albicans has developed virulence
factors, such as FH binding molecules, enabling it to functionally
mimic human cells (Phan et al., 2007), thereby limiting the
attack of the immune system, e.g., complement, during blood
dissemination (Luo et al., 2011). Examples are C. albicans
binding to plasminogen, increasing its ability to disseminate
(Crowe et al., 2003), or binding to C4BP, enabling it to regulate
complement classical and lectin pathways on its surface (Meri
et al., 2004).
Factor H represents the main inhibitor of the alternative
pathway of complement and C. albicans has evolved FH binding
molecules on its surface (Poltermann et al., 2007; Luo et al., 2010,
2013). At least one of these FH binding molecules, pH-regulated
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FIGURE 5 | Decreased FH binding is associated with increased C3b/iC3b
deposition on C. albicans. Relative C3b/iC3b deposition on SN152 parental
(black bar), hgt11/1 (white bar), hgt11/1::HGT1 (complemented strain),
each incubated with NHS, or on SN152 incubated with anti-Hgt1p or with the
chimeric molecule FH6.7/Fc to block FH binding, or with irrelevant rabbit
anti-human IgG. Data are expressed as MFI normalized to SN152 parental
strain. Each bar represent the normalized mean + SD of five separate
experiments ∗p < 0.05, ∗∗p < 0.01, by one-way ANOVA, using SN152 for
comparison.
antigen 1 (Pra1), can be released into the host environment to
inhibit the immune response by binding to C3 and preventing
its conversion (Luo et al., 2010). In a previous study, the
transmembrane protein Hgt1p, was identified as a FH binding
molecule in C. albicans by screening a cDNA expression library
(Lesiak-Markowicz et al., 2011). Hgt1p is characterized by 12
transmembrane domains and plays its canonical role in glucose
metabolism on the cellular membrane (Fan et al., 2002). A null
mutant strain, hgt11/1, has been constructed earlier and, similar
to our current observations, also showed a decrease in FH
binding (Lesiak-Markowicz et al., 2011). These data together
confirm the non-canonical role of the Hgt1p as FH binding
molecule (Lesiak-Markowicz et al., 2011), and establish its role
as a virulence factor by inhibiting the complement system on
C. albicans.
In order to assess whether the blocking of Hgt1p is a
strategy to limit the complement inhibition, an antibody able
to detect an epitope in the extracellular part of Hgt1p was
generated commercially. To study the effects of the complement
inhibition by Hgt1p, we focussed on FH deposition, C3b/iC3b
conversion and deposition on the yeast’s surface, phagocytosis,
and killing by human PMNs. Blocking FH-Hgt1p interactions
by a specific antibody, resulted in FH displacement (Figure 4B)
and an increased C3b/iC3b conversion and deposition on
the surface (Figure 5), similar to that displayed by hgt11/1.
FH domains 6 and 7 encompass the sites of binding used
by streptococci (Blackmore et al., 1998), Neisseria (Madico
et al., 2006) and non-typeable Haemophilus influenzae (Wong
et al., 2016) among other pathogens to inhibit the complement
alternative pathways (Blom et al., 2017). We therefore used a
chimeric molecule, consisting of human FH domains 6 and
7 fused with the human IgG Fc receptor (Shaughnessy et al.,
2014), and demonstrated that this functions as another useful
FH blocker thereby confirming our initial hypothesis. However,
incubations with blockers did not affect growth (Supplementary
Figure S5).
FH6.7/Fc has shown efficacy against N. meningitidis
(Shaughnessy et al., 2014), N. gonorrhoeae (Shaughnessy
et al., 2018), non-typeable Haemophilus influenzae (Wong
et al., 2016), and group A streptococci in rodent models
(Blom et al., 2017). Our data support further evaluation
of FH6.7/Fc as an immunotherapeutic against C. albicans.
Activation of the classical pathway through the Fc domains
present in anti-Hgtp1 and FH6.7/Fc may contribute to C3b/iC3b
deposition and phagocytosis through FcγR engagement, in
addition to enhancement of alternative pathway activation
by blocking FH access to the fungal surface. Compared to
anti-Hgt1p, FH6.7/Fc was slightly more effective in preventing
FH deposition and enhancing phagocytosis which may be due
to the fact that this chimeric molecule may also target other
FH binding molecules expressed by C. albicans (Poltermann
et al., 2007; Luo et al., 2010, 2013). However, the presence
of Hgt1p not only on the cell membrane and cell wall, but
also on secreted exosomes may interfere with this evasion
mechanism, acting as a decoy that diverts FH away from fungal
surface.
Phagocytosis by human PMNs was investigated as it represents
the first line of innate immune defense against pathogens, such
as C. albicans (Gazendam et al., 2016). The αMβ2 integrin (β2
INT) CD11b/CD18 or complement receptor 3 (CR3) on PMNs
plays a major role in increasing the adhesion to C. albicans by
β-glucan binding (O’Brien and Reichner, 2016). It also binds to
the iC3b which opsonises the yeast during complement attack
(Ueda et al., 1994). The recognition of the fungal cell wall
constituents together with the deposited iC3b generates a marked
response toward the yeast, mediated by transduction pathways
and leading to PMN-mediated fungal killing (Gazendam et al.,
2016).
Our previous study revealed that Hgt1p is a CR3 analog
(Lesiak-Markowicz et al., 2011). The specific iC3b binding to
a CR3 like molecule on C. albicans may limit iC3b surface
deposition and thus also phagocytosis. In order to assess whether
FH blocking represents a tool to increase the fungal killing,
a co-culture of all yeast strains used in this study with fresh
PMNs from healthy human donors was undertaken. The results
revealed a significant higher degree of hgt11/1 phagocytosis in
comparison to that of the parental strain. When specific blockers
were applied to the parental strain, in vitro phagocytosis was
similar to that induced by the hgt11/1 null mutant. This may
imply that appropriate antibodies might be able to limit FH
access and increase C3b/iC3b deposition and phagocytosis of the
yeast.
In order to assess whether the increased phagocytosis of the
parental strain coated by anti-Hgt1 is due to the blockage of
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FIGURE 6 | Factor H binding contributes to evasion of phagocytosis by PMNs of C. albicans at physiological glucose concentrations. (A) Scatter (density) plots from
a representative experiment showing association of FITC-labeled yeast with PMNs as measured by FACS. The density plots show fluorescence (FITC) on the X-axis
as a measure of PMNs with associated C. albicans. The Y-axis shows side scatter. The constituents of each reaction are indicated above each histogram. All
reactions contain NHS. (B) Cumulative data to show that loss or decreased FH binding to C. albicans is associated with increased phagocytosis. (C) PMN
medicated killing performed under similar conditions as indicated in (B). Bars represent the normalized mean + SD of four separate experiments. The % of PMNs
with associated yeast in (B) is normalized to PMNs co-incubated parental strain SN152 plus NHS. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, by one-way ANOVA,
using SN152 for comparison.
Hgt1p-FH binding or due to the Fc receptor recognition by
PMNs, single Fab fragments of the antibody were generated
which also significantly increased phagocytosis of the parental
strain to a similar extent as anti-Hgt1p whole antibody (data not
shown).
Even more pronounced phagocytosis by PMNs was observed
using the chimeric molecule FH6.7/Fc, confirming the role of
FH binding molecules on C. albicans as complement evasion
molecules. The killing assay confirmed the phagocytosis results
and corroborated the role of Hgt1p as virulence factor. High
expression of Hgt1p was also detected by immunofluorescence
on SN152 hyphae (data not shown). Blocking of Hgt1p may thus
also represent an additional tool to prevent tissue invasion by
C. albicans. All these findings support further testing in a mouse
infection model.
So far there are no antibody-based therapies available in the
treatment of C. albicans. Mycograb (NeuTec Pharma, a subsidiary
of Novartis AG, Basel, Switzerland) is a human-derived single
chain recombinant antibody fragment against C. albicans
heat shock protein 90 (Hsp90), a stress induced protein
(Burt et al., 2003) involved in intracellular processes, but
also detected on the cell wall (Chaffin et al., 1998). Several
in vitro studies have shown that the effect of classic antifungal
treatment can be enhanced by Mycograb, which decreases
the minimal inhibiting concentration (MIC) of the yeast to
antifungals (Bugli et al., 2013). This combination between
antifungals and Mycograb has decreased mortality in patients
with invasive Candida infection in a small randomized trial
(Pachl et al., 2006), but it is still not approved for clinical
use.
FIGURE 7 | Schematic representation of Hgt1p complement inhibition model.
Hgt1p is carried to the cell wall by exosomes. The protein crosses the cell wall
and acts as a FH binding molecule. Blockage of FH binding and the resulting
up-regulation of C3b/iC3b conversion and deposition on fungal surface
increases phagocytosis by PMNs.
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The blocking of evasion on the fungal surface (Figure 7) may
represent a first step toward developing more specific ways to
treat human infection caused by fungi. Hgt1p may form a starting
point for novel antifungal therapies that target specific molecules
involved in pathogenesis.
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